Clinical Trials

Inclusion Criteria:

• Have a confirmed GRN mutation with or without a FTLD clinical syndrome (see below) or are a member of a family with a strong medical history of an FTLD syndrome.
• Age 18 years of age or greater (preferably at least 30 because symptoms rarely develop before then).
• Must be able to complete all of study procedures.
• Must be sufficiently fluent in English to complete all measures.
• Must be willing and able to consent to the protocol and undergo up to 3 visits, which will occur approximately every 6 months.
• Will be co-enrolled in the ALLFTD study.

Exclusion Criteria:

• Known presence of a structural brain lesion (e.g., tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic participant.
• Known presence of an Alzheimer’s disease-causing mutation in PSEN1, PSEN2 or APP; or biomarker evidence for Alzheimer’s disease as a cause of the clinical syndrome.
• The participant cannot complete all study procedures.
• Subject is unwilling to return for follow-up.
• Subject has a contraindication for MRI or FDG-PET.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/20/23. Questions regarding updates should be directed to the study team contact.